Drug name

Fostair® (beclometasone/formoterol pressurised metered dose inhaler)

Indication

• Fostair is indicated in the regular treatment of asthma in adults where use of a combination product (ICS and LABA) is appropriate for:1
  – patients not adequately controlled with ICS and ‘as needed’ inhaled short-acting beta2-agonist or
  – patients already adequately controlled on both ICS and LABA.

NB Fostair is not appropriate for treatment of acute asthma attacks.

Dosage

• One or two inhalations to be taken twice daily.1

NICE recommendations

• For adults with chronic asthma in whom treatment with an ICS and LABA is considered appropriate, the following apply:2
  – The use of a combination device within its marketing authorisation is recommended as an option
  – If a combination device is chosen then the least costly device that is suitable for the individual is recommended.

BTS/SIGN recommendations

Step 3: initial add-on therapy

• Add-on therapy is indicated when there is inadequate control on low-dose ICS3
• First choice of add-on therapy is the addition of an inhaled LABA, which improves lung function and symptoms, and decreases exacerbations3
• Many patients will benefit more from add-on therapy than from increasing ICS above 200 μg BDP/day3

Evidence for use

• Combination inhalers have the advantage of guaranteeing that the LABA is not taken without ICS.3

• Fostair:
  – reduces use of rescue medication and improves asthma symptoms in patients previously uncontrolled at Step 2 of the BTS/SIGN guideline4–7
  – is the first fixed-combination inhaler to demonstrate a statistical superiority in asthma control versus its separate components8
  – is less expensive than comparable doses of Symbicort® or Seretide™9

• Fostair 100/6 (two puffs bd) has been shown to be comparable to Symbicort® 200/6 (two puffs bd) and Seretide™ 125 Evohaler™ (two puffs bd)4,5,9

• Fostair contains quick-acting formoterol, which triggers the bronchodilatory effect within 1–3 minutes1
  – 100 μg BDP extrafine in Fostair is equivalent to 250 μg BDP in a non-extrafine formulation.

Contraindications and precautions

Fostair:1

• is contraindicated in patients with a known hypersensitivity to the active substances or any of the excipients
• should be used with caution in patients with cardiovascular disorders including arrhythmias and QTc prolongation, thyrotoxicosis, diabetes, phaeochromocytoma, untreated hypokalaemia, tuberculosis, and fungal and viral infections (see prescribing information).

Common side-effects

• Common side-effects include pharyngitis, headache, and dysphonia (see prescribing information for full details).1

Budgetary implications

• Volume and costs of combination inhalers are increasing year on year and are one of the highest classes of spend10,11

ICS=inhaled corticosteroid; LABA=long-acting beta2-agonist; BDP=beclometasone dipropionate

---

This formulary decision guide was developed from content provided by Chiesi Limited in a format developed by Guidelines in Practice. It has been reviewed by a member of the Guidelines in Practice editorial board. At all times editorial control has remained with Guidelines in Practice.
Formulary decision guide: Fostair® (beclometasone/formoterol pressurised metered dose inhaler)

**Key points**

**Fostair:**
- reduces use of rescue medication and improves asthma symptoms in patients previously uncontrolled at Step 2 of the BTS/SIGN guideline 4–7
- is the first fixed-combination inhaler to demonstrate a statistical superiority in asthma control versus its separate components. 8

References


Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Chiesi Limited. (address as above) Tel: 0161 488 5555

NICE guidance states that ‘if a combination device is chosen then the least costly device that is suitable for the individual is recommended’.  8

Fostair has the lowest acquisition cost of dose-comparable combination inhalers 9

- It is estimated that:  
  - 75% of asthma admissions are preventable
  - patients who do not have a written asthma action/management plan are four times more likely to require hospital treatment.

Fostair® (beclometasone dipropionate and formoterol fumarate dihydrate pressurised inhalation solution)

Please refer to Summary of Product Characteristics (SmPC) before prescribing

Prescribing information

Presentations: Pressurised inhalation solution containing 100 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate dihydrate per actuation.  

Indications: Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta -agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and/or needed: inhaled short-acting beta, agonist; or patients already adequately controlled on both inhaled corticosteroids and long-acting beta -agonists. Not appropriate for treatment of acute asthma attacks. Dosage and Administration: For inhalation use only. Fostair is not intended for the initial management of asthma. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of beta -agonists and/or corticosteroids by patient should require a combination of doses other than those available in the Dosage and Administration: 

- 17 years of age. Therefore Fostair is not recommended for children and adolescents under 18 years:  
  - of Fostair has not yet been established. No data are available with Fostair in children 17 years of age. Therefore Fostair is not recommended for children and adolescents under 18 years:  
  - Pregnancy and Lactation:  
  - breastfed infants.  
  - Corticosteroids may occur, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhaled than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract, glaucoma and more rarely a range of psychological or behavioural effects (particularly in children). Titrate to the lowest dose at which effective control of asthma is maintained to minimise systemic effects. Special care is needed in transferring patients from oral steroids. Fostair contains a small amount of ethanol (approximately 7mg per actuation); at normal doses the amount of ethanol is negligible and does not pose a risk to patients. Patients should rinse mouth after inhalation to minimise risk of oropharyngeal candida infection.  
  - Interactions: Beclometasone dipropionate undergoes a very rapid metabolism via esterase enzymes without involvement of the cytochrome p450 system. Avoid beta-blockers (including eye drops). Caution is required when theophylline or other beta-adrenergic drugs are prescribed concomitantly with formoterol. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antimhistamines, MAOIs and TCAs can prolong the QTC interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance. Concomitant administration with MAOIs, including agents with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions. Risk of arrhythmias in patients receiving anaesthesia with halogenated hydrocarbons. Theoretical potential for interaction in sensitive patients taking disulfiram or metronidazole.  
  - Pregnancy and Lactation: No relevant clinical data. Should only be used during pregnancy or lactation if the expected benefits outweigh the potential risks. It is desirable:  
  - Common: dyspareunia, headache, dizziness, gastrointestinal disorders including diarrhea, nausea, pruritus, rash, rhinitis, sinusitis, vomiting.  
  - Very rare: atrial fibrillation, dyspnoea, exacerbation of asthma, growth retardation in children and adolescents, oedema peripheral, bone density decreased.  
  - Unknown:  
  - side effects. Contraindications: Hypersensitivity to any of the components. Warnings and Precautions: Cardiovascular disorders including cardiac arrhythmias and QTc prolongation, thyrotoxicosis, diabetes mellitus, phaeochromocytoma, untreated hypokalaemia, acute or quiescent pulmonary tuberculosis, fungal and viral infections. Fostair should not be used as the first treatment for asthma, should not be initiated during an exacerbation, or during significantly worsening or acutely deteriorating asthma, and should not be stopped abruptly. If patients find the treatment ineffective medical attention must be sought. Paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing, treat immediately. Patients should take Fostair as prescribed even when asymptomatic. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhaled than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract, glaucoma and more rarely a range of psychological or behavioural effects (particularly in children). Titrate to the lowest dose at which effective control of asthma is maintained to minimise systemic effects. Special care is needed in transferring patients from oral steroids. Fostair contains a small amount of ethanol (approximately 7mg per actuation); at normal doses the amount of ethanol is negligible and does not pose a risk to patients. Patients should rinse mouth after inhalation to minimise risk of oropharyngeal candida infection. Interactions: Beclometasone dipropionate undergoes a very rapid metabolism via esterase enzymes without involvement of the cytochrome p450 system. Avoid beta-blockers (including eye drops). Caution is required when theophylline or other beta-adrenergic drugs are prescribed concomitantly with formoterol. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antimhistamines, MAOIs and TCAs can prolong the QTC interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance. Concomitant administration with MAOIs, including agents with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions. Risk of arrhythmias in patients receiving anaesthesia with halogenated hydrocarbons. Theoretical potential for interaction in sensitive patients taking disulfiram or metronidazole.  
  - Pregnancy and Lactation:  
  - Common: dyspareunia, headache, dizziness, gastrointestinal disorders including diarrhea, nausea, pruritus, rash, rhinitis, sinusitis, vomiting.  
  - Very rare: atrial fibrillation, dyspnoea, exacerbation of asthma, growth retardation in children and adolescents, oedema peripheral, bone density decreased.  
  - Unknown:  
  - side effects. Contraindications: Hypersensitivity to any of the components. Warnings and Precautions: Cardiovascular disorders including cardiac arrhythmias and QTc prolongation, thyrotoxicosis, diabetes mellitus, phaeochromocytoma, untreated hypokalaemia, acute or quiescent pulmonary tuberculosis, fungal and viral infections. Fostair should not be used as the first treatment for asthma, should not be initiated during an exacerbation, or during significantly worsening or acutely deteriorating asthma, and should not be stopped abruptly. If patients find the treatment ineffective medical attention must be sought. Paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing, treat immediately. Patients should take Fostair as prescribed even when asymptomatic. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhaled than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract, glaucoma and more rarely a range of psychological or